MSD: As we approach peak revenue for some approved indications, Keytruda's growth is expected to slow.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.